Lymphoma Clinical Trials in Nashville

Showing 241-260 of 564 trials

Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk

NCT03436862

This is a Phase II single-arm open-label study of nivolumab as maintenance therapy after autologous stem cell transplantation in patients with Hodgkin lymphoma at risk of relapse or progression.

Hodgkin Lymphoma

SCRI Development Innovations, LLC37 participantsStarted May 2018

Denver, Colorado, United States • Kansas City, Missouri, United States • Nashville, Tennessee, United States +3 more locations

COMPLETEDPhase 2< 1 mile

Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)

NCT02181738

The purpose of this study is to evaluate the efficacy and safety of Nivolumab in previously treated (cohorts, A, B \& C) or newly diagnosed (cohort D) classical Hodgkin Lymphoma participants.

Hodgkin Disease

Bristol-Myers Squibb294 participantsStarted Aug 2014

Los Angeles, California, United States • Los Angeles, California, United States • Atlanta, Georgia, United States +35 more locations

Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk

Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)

Lymphoma Trials in Other Cities

Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma

A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma

A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors

Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma

Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma

An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies

Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies

A Study of BTX-1188 in Subjects With Advanced Malignancies

Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma

CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma

PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine)

Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL

A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma

GB5121 in Adult Patients With Relapsed/Refractory CNS Lymphoma

A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)

Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies

Other Conditions in Nashville